Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Premium
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • PorteføljeInderes modelportefølje
  • Lær om investering
    • AnalyseskoleLær at læse og forstå aktieanalyse
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsidertransaktionerFølg købs- og salgsaktivitet fra virksomhedsinsidere
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Virtuel analytiker-chatStil spørgsmål og få AI-drevne investeringsindsigter med det samme
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Remedy extensive report: Checkpoint reached, heading towards the next platform leap

REMEDYOmfattende analyse19.11.2026, 10.18
Atte RiikolaAnalytiker
Discuss
Læs hele rapporten

Oversigt

  • The analyst reiterates the EUR 21.0 target price and upgrades Remedy to Buy from Accumulate following the share price decline.
  • Control Resonant sold over 1 million copies in about three weeks, Remedy’s fastest-selling game. The analyst expects it to be highly profitable and says the launch reduces short-term risk and enables future self-publishing.
  • Although hit-game upside did not materialize, the analyst considers the valuation attractive at 2027e–2028e EV/EBITDA of 8x–6x. The DCF base-case value is EUR 22.8.
  • The analyst forecasts 2027 revenue of 113 MEUR and EBITDA of 23.2 MEUR, rising to 32.3 MEUR in 2028. Game sales and release timing will keep results volatile.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 11/19/2026 at 8:00 am EET

We reiterate our EUR 21.0 target price for Remedy, but following the share price drop, we update our recommendation to Buy (was Accumulate). Control Resonant has been successfully launched, and although the hit game option did not materialize, we estimate the game will be a commercially highly profitable project for Remedy. The successful launch of Resonant also reduces Remedy's short-term risks and, in our view, enables the self-publishing of future projects. Relative to this potential, we find the share valuation highly attractive.

An independent AAA game developer and publisher

In 2017, Remedy began its transition to a multi-project model and a journey up the value chain from a subcontractor to an independent game developer and publisher. Since then, much progress has been made, and the company now has the resources and capabilities to develop two projects simultaneously in full production. The company has also built the capabilities to self-publish its own games. As a result, the revenue and profit potential of games for Remedy is significantly higher than in previous game projects. Control Resonant, launched in September 2026, was Remedy's first self-published major single-player game. The game received good reviews (Metacritic 83), and players have received it even better than critics. The game sold over a million copies in about three weeks, making it the fastest-selling game in Remedy's history. Regarding future game releases, the company has Max Payne 1&2 Remake in full production under the subcontracting model, which we expect to be released in early 2027. In addition, the company has an as-yet-unnamed game project in the production readiness stage, which we expect to be Alan Wake 3.

More major game releases ahead in coming years

Remedy guides for 2026 revenue and EBITDA to increase year-on-year. Based on our estimates (2026e revenue 99.7 MEUR, EBITDA 15.9 MEUR), the guidance is clearly beaten following the release of Control Resonant. However, as depreciation increases, EBIT will still remain slightly unprofitable. For 2027, we expect revenue to grow to 113 MEUR and EBITDA to rise to 23.2 MEUR. Growth is supported by the long tail of sales for Control Resonant. In addition, Remedy's share of the game's proceeds will increase once Annapurna's share of the production budget has been recouped. According to our estimates, royalties from Max Payne 1&2 Remake will begin in the second half of 2027. Of the company's 2027 targets, doubling revenue from the 2024 level is met in our estimates, but the EBITDA margin (2027e: 20.6%) falls short of the 30% target. In 2028, we expect EBITDA to rise to 32.3 MEUR (26.2% of revenue). This is driven by Max Payne royalties and the next self-published game, which we expect to be released at the end of the year. Exact visibility into game sales and royalties is weak, and the timing of game releases will continue to cause volatility in Remedy's figures for years to come.

The successful launch of Control Resonant reduced risks, even though the hit game option did not materialize

The successful launch of Control Resonant has, in our view, reduced Remedy's risks, as the scenario of a failed launch is now off the table. We estimate that the game's cash flows, together with a strong balance sheet, will enable the financing and self-publishing of subsequent projects. On the other hand, the hit game option did not materialize, and the short-term element of surprise has been partly priced out of the share. However, based on our estimates for the coming years, the share valuation (2027e-2028e EV/EBITDA of 8x-6x) looks very low following the share price decline. The long-term potential is indicated in part by the base-case value of our DCF model (EUR 22.8). Over the next 12 months, we estimate that the share will be supported by the continuation of Resonant's sales and the likely launch of Max Payne Remake. In addition, further information on Remedy's subsequent game projects may be provided.

Læs hele rapporten

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Læs mere på virksomhedsside

Key Estimate Figures18.11

202526e27e
Omsætning59,599,7112,7
vækst-%17,5 %67,6 %13,0 %
EBIT (adj.)-14,9-0,68,5
EBIT-% (adj.)-25,0 %-0,6 %7,5 %
EPS (adj.)-0,96-0,110,48
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.33,0
EV/EBITDA17,212,98,6

Forumopdateringer

Personligt forventer jeg, at de trods dette snupper 1-2 statuetter. GOTY er sandsynligvis en formsag, som GTA6 tager, men i de andre kategorier...
for 8 timer siden
af Jarnis
8
Hyvää huomenta Remedy-ketjuun! Nyt olisi tarjolla tuoretta laajaa raporttia uudessa digimuodossa. Oli itselle nyt ensimmäinen testi tuon meid...
for 14 timer siden
af Atte Riikola
44
Faldt forresten over denne artikel, hvor en ny oplysning er, at Resonant holdt sig ganske pænt inden for sit produktionsbudget på €50M – eller...
i går
17
Jep. Selvom der blev joket med det i sin tid, gjorde hele branchen i sidste ende det helt rigtige ved at undgå dette udgivelsesvindue i november...
i går
12
Det anmeldelsesgennemsnit for GTA 6 er helt vanvittigt, så hvis Resonant opnår flere runner-up-placeringer, må man sgu bare være tilfreds med...
i går
af Arvuuttaja
1
Præcis. Control Resonant er ikke nomineret i nogen kategorier, hvor GTA6 ikke også er nomineret. Hvis GTA6 rydder bordet og tager alle priserne...
i går
af Vinski74
1
Fordi GTA tager absolut al medieplads i øjeblikket, og det samme vil fortsætte ved Awardsshowet, når det vinder GOTY.
i går
af supremegod
4